Stock price doubled and then reached a tipping point, GRAND PHARMA (00512) innovative eye drugs landed in Macau, and approval for the Greater Bay Area is imminent.

Due to positive news driving it, the stock price of GRAND PHARMA (00512) has been rising steadily since May and reached a historical high of 9.20 Hong Kong dollars on May 23, with an increase of nearly 50% within the month. Compared to the low point at the beginning of the year, it has more than doubled in growth. On May 25, the company once again received positive progress related to a major product, its global innovative ophthalmic drug GPN01768 (TP-03, Latarana eye drops, 0.25%) used for treating Demodex blepharitis, has been approved for sale in Macau, China. This will provide a new treatment option for Demodex blepharitis patients in the region. GPN01768 is the world's first and only FDA-approved innovative drug for the treatment of Demodex blepharitis. GRAND PHARMA has exclusive development, production, and commercialization rights for the drug in Greater China. The product's New Drug Application (NDA) in China has been accepted by the National Medical Products Administration. The approval of GPN01768 in Macau not only provides momentum for its future listing in the Greater Bay Area of Guangdong, Hong Kong, and Macau, but also is expected to further promote its landing in mainland China. With overseas sales surpassing one billion, potential products reaching billions of molecules are filling global market gaps. Demodex blepharitis is a chronic inflammatory disease caused by Demodex infestation of the eyelids, mainly affecting the eyelid skin, eyelash follicles and glands, and the meibomian glands. The disease causes significant damage to the eyelids, is prone to recurrent bouts, and is contagious, leading to decreased lipid secretion, reduced tear film stability, and ultimately causing dry eye syndrome. Data shows that the detection rate of Demodex blepharitis is over 80% in patients with dry eye syndrome, and there is a trend towards younger patients. A study involving 335 patients with eye discomfort showed that 84% of patients had Demodex in their eyes, and the quantity of Demodex was significantly positively correlated with subjective eye discomfort. As an infectious disease, Demodex blepharitis affects hundreds of millions of patients worldwide, with an incidence rate varying from 41% to 79% globally. Frost & Sullivan data shows that in 2021, there were approximately 468 million Demodex blepharitis patients globally, and it is projected that by 2025 and 2030, the global number of patients will reach around 485 million and 506 million, with Chinese patients estimated to increase to 59.5 million and 59.8 million by 2025 and 2030, respectively. Despite the large number of patients, there is currently no specific treatment for this disease, only medications such as tea tree oil preparations designed for local mite removal, with long treatment periods and difficulty i...In November 2024, the domestic Phase III clinical study of the innovative improved new drug GPN00153 (CBT-001) for the treatment of pterygium was completed and achieved the clinical endpoint; the first patient was dosed in the Chinese Phase III clinical study in March 2024, and all patients will be dosed by June this year. The global innovative ophthalmic drug GPN00884, used to delay the progression of myopia in children, had the first patient dosed in the Chinese Phase I clinical study in June 2024.Meanwhile, in the field of nuclear medicine for anti-tumor diagnosis and treatment, GRAND PHARMA also achieved great success. Since May, the company's nuclear medicine sector has made frequent progress, with the clinical research data of Yttrium [90Y] Microspheres Injection of Yttrium [90Y] Microspheres Injection of Yitgan Tai recently successfully presented at the American Society of Clinical Oncology (ASCO), the most influential conference in the global oncology field. The data came from the team led by academician Dong Jiahong from Chang Gung Memorial Hospital, Tsinghua University, and the team led by Professor Zhang Hui from the First Affiliated Hospital of the Army Medical University; at the same time, 15 related research results were included in the 2025 Asia-Pacific Primary Liver Cancer Expert Conference (APPLE). This means that GRAND PHARMA's Yitgan Tai Yttrium [90Y] Microspheres Injection has been highly recognized by the industry and the international academic community. GRAND PHARMA's nuclear medicine research and production base in Wenjiang, Chengdu, recently received a Class A "Radiation Safety License" issued by the National Ecological Environment Department, and will officially start operations in June of this year. It is reported that the base is the world's first closed-loop platform for the nuclear medicine industry chain, with a total planned investment of over 3 billion yuan, focusing on core areas such as isotope process development and preparation, nuclear medicine coupling technology, and automated labeling technology, covering nuclear medicine early research, process development, quality research, preclinical research, intelligent production, and precise distribution. It has established a world-class research and development production quality and operation system, with 14 production lines that meet the requirements of Good Manufacturing Practice (GMP) for drug production, and has built a full-chain AI operation system and intelligent manufacturing system. It can achieve independent production of various isotopes and nuclear medicine formulations, while also reserving production lines for alpha isotope drugs. It is currently one of the most comprehensive and highly automated intelligent factories in the world in terms of isotopes, and can fully meet the diverse and large-scale preparation needs for therapeutic and diagnostic nuclear medicines. As GRAND PHARMA's technological innovation breakthrough approaches, the capital market has already captured the historic opportunity of the company's "original innovation" transformation in advance. Several research institutions have raised their stock price expectations for the company, with China International Capital Corporation raising GRAND PHARMA's target price three times this year, with the latest target price being 9.6 Hong Kong dollars. Huatai has given an even higher target price of 10.15 Hong Kong dollars. The innovative products and advancements in various business sectors are already showing promising results: GRAND PHARMA's years of deep cultivation of innovative strategies have borne fruit, and are now poised to contribute to the company's long-term development, bringing more abundant momentum for the company's performance growth.